Related Experiment Video
Updated: Dec 3, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Brain energy metabolism and multiple sclerosis: progress and prospects
Sung Jean Park1, Ji Woong Choi2
1College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, 191 Hambakmoero, Yeonsu-gu, Incheon, 21936, Korea. psjnmr@gachon.ac.kr.
Abstract:
Multiple sclerosis (MS) is an autoimmune disease accompanied with nerve pain and paralysis. Although various pathogenic causes of MS have been suggested, including genetic and environmental factors, how MS occurs remains unclear. Moreover, MS should be diagnosed based on clinical experiences because of no disease-specific biomarker and currently available treatments for MS just can reduce relapsing frequency or severity with little effects on disease disability. Therefore, more efforts are required to identify pathophysiology of MS and diagnosis markers. Recent evidence indicates another aspect of MS pathogenesis, energy failure in the central nervous system (CNS). For instance, inflammation that is a characteristic MS symptom and occurs frequently in the CNS of MS patients can result into energy failure in mitochondria and cytosol. Indeed, metabolomics studies for MS have reported energy failure in oxidative phosphorylation and alteration of aerobic glycolysis. Therefore, studies on the metabolism in the CNS may provide another insight for understanding complexity of MS and pathogenesis, which would facilitate the discovery of promising strategies for developing therapeutics to treat MS. This review will provide an overview on recent progress of metabolomic studies for MS, with a focus on the fluctuation of energy metabolism in MS.
Insights
Multiple sclerosis (MS) involves nerve damage and is not fully understood. New research highlights energy metabolism dysfunction in the central nervous system (CNS) as a key factor in MS pathogenesis.
Area of Science:
- Neuroscience
- Immunology
- Metabolomics
Background:
- Multiple sclerosis (MS) is an autoimmune disease causing nerve pain and paralysis.
- Current MS diagnosis relies on clinical experience due to a lack of specific biomarkers.
- Existing treatments offer limited impact on disease progression and disability.
Purpose of the Study:
- To review recent advances in metabolomic studies concerning MS.
- To focus on the role of energy metabolism fluctuations in MS pathogenesis.
- To explore potential new diagnostic and therapeutic strategies for MS.
Main Methods:
- Review of current literature on metabolomics in multiple sclerosis.
- Analysis of studies investigating energy metabolism in the central nervous system (CNS) of MS patients.
- Examination of findings related to mitochondrial and cytosolic energy failure.
Main Results:
- Inflammation in MS patients' CNS can lead to energy failure in mitochondria and cytosol.
- Metabolomics studies reveal impaired oxidative phosphorylation and altered aerobic glycolysis in MS.
- Evidence points to energy metabolism disruption as a significant aspect of MS pathogenesis.
Conclusions:
- Understanding CNS energy metabolism alterations offers new insights into MS complexity.
- Metabolomic approaches may identify novel biomarkers for MS diagnosis.
- Targeting energy metabolism dysfunction presents a promising therapeutic avenue for MS.

